The association between neutrophil gelatinase-associated lipocalin and clinical outcome in chronic heart failure: Results from CORONA

Journal of Internal Medicine

Volumn 271, Issue 5, 2012, Pages 436-443

  Nymo, S H ^a,b   Ueland, T ^a,c   Askevold, E T ^a,b   Flo, T H ^d   Kjekshus, J ^a,b   Hulthe, J ^e,f   Wikstrand, J ^e   McMurray, J ^g   Van Veldhuisen, D J ^h   Gullestad, L ^a,b,c   Aukrust, P ^a,c   Yndestad, A ^a,b,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Centre for Heart Failure Research   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f ASTRAZENECA R AND D   (Sweden)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cardio renal syndrome; Controlled rosuvastatin multinational trial in heart failure; Heart failure; Inflammation; Neutrophil gelatinase associated lipocalin

Indexed keywords

ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN A1; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIGITALIS; DIGITOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PLACEBO; ROSUVASTATIN; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STROKE;

ACUTE-PHASE PROTEINS; AGED; APOLIPOPROTEIN A-I; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHRONIC DISEASE; FEMALE; FLUOROBENZENES; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOCALINS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; NORWAY; PATIENT READMISSION; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PYRIMIDINES; SEVERITY OF ILLNESS INDEX; SULFONAMIDES;

EID: 84860243955     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02503.x     Document Type: Article

References (28)

1. Yndestad A, Damås J, Øie E, Ueland T, Gullestad L, Aukrust P. Role of inflammation in the progression of heart failure. Curr Cardiol Rep 2007; 9: 236-41.
2. Iwanaga Y, Miyazaki S. Heart failure, chronic kidney disease, and biomarkers: -an integrated viewpoint. Circ J 2010; 74: 1274-82.
3. Butler J, Chirovsky D, Phatak H, McNeill A, Cody R. Renal function, health outcomes, and resource utilization in acute heart failure. Circ Heart Fail 2010; 3: 726-45.
4. Kjeldsen L, Johnsen AH, Sengeløv H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993; 268: 10425-32.
5. Eagan TM, Damås J, Ueland T et al. Neutrophil gelatinase-associated lipocalin: a biomarker in COPD. Chest 2010; 138: 888-95.
6. Alpízar-Alpízar W, Laerum O, Illemann M et al. Neutrophil gelatinase-associated lipocalin (NGAL/Lcn2) is upregulated in gastric mucosa infected with Helicobacter pylori. Virchows Arch 2009; 455: 225-33.
7. Nielsen BS, Borregaard N, Bundgaard JR, Timshel S, Sehested M, Kjeldsen L. Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut 1996; 38: 7.
8. Yndestad A, Landrø L, Ueland T et al. Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur Heart J 2009; 30: 1229-36.
9. Ding L, Hanawa H, Ota Y et al. Lipocalin-2/neutrophil gelatinase-B associated lipocalin is strongly induced in hearts of rats with autoimmune myocarditis and in human myocarditis. Circ J 2010; 74: 523-30.
10. Flo TH, Smith KD, Sato S et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 2004; 432: 917-21.
11. Xu S, Venge P. Lipocalins as biochemical markers of disease. Biochim Biophys Acta 2000; 1482: 298-307.
12. Bolignano D, Coppolino G, Lacquaniti A, Buemi M. From kidney to cardiovascular diseases: NGAL as a biomarker beyond the confines of nephrology. Eur J Clin Invest 2010; 40: 273-6.
13. Devarajan PRAS. Review: neutrophil gelatinase-associated lipocalin: a troponin-like biomarker for human acute kidney injury. Nephrology 2010; 15: 419-28.
14. Damman K, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL. Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. Eur J Heart Fail 2008; 10: 997-1000.
15. Damman K, Van Veldhuisen DJ, Navis G et al. Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart 2010; 96: 1297-302.
16. Damman K, Masson S, Hillege HL et al. Clinical outcome of renal tubular damage in chronic heart failure. Eur Heart J 2011; 32: 2705-12.
17. Maisel AS, Mueller C, Fitzgerald R et al. Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail 2011; 13: 846-51.
18. Shrestha K, Borowski AG, Troughton RW, Thomas JD, Klein AL, Tang WH. Renal dysfunction is a stronger determinant of systemic neutrophil gelatinase-associated lipocalin levels than myocardial dysfunction in systolic heart failure. J Card Fail 2011; 17: 472-8.
19. Kjekshus J, Apetrei E, Barrios V et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248-61.
20. Wedel H, McMurray JJV, Lindberg M et al. Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart Fail 2009; 11: 281-91.
21. Smilde TDJ, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL. Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation 2006; 114: 1572-80.
22. Pedersen KR, Ravn HB, Hjortdal VE, Nørregaard R, Povlsen JV. Neutrophil gelatinase-associated lipocalin (NGAL): validation of commercially available ELISA. Scand J Clin Lab Invest 2010; 70: 374-82.
23. Landrø L, Damås JK, Flo TH et al. Decreased serum lipocalin-2 levels in human immunodeficiency virus-infected patients: increase during highly active anti-retroviral therapy. Clin Exp Immunol 2008; 152: 57-63.
24. Pencina MJ, D'Agostino RB, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011; 30: 11-21.
25. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
26. McMurray JJV, Kjekshus J, Gullestad L et al. Effects of statin therapy according to plasma high-sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Circulation 2009; 120: 2188-96.
27. Schmidt-Ott KM, Mori K, Li JY et al. Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 2007; 18: 407-13.
28. Grigoryev DN, Liu M, Hassoun HT, Cheadle C, Barnes KC, Rabb H. The local and systemic inflammatory transcriptome after acute kidney injury. J Am Soc Nephrol 2008; 19: 547-58.